TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02490605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal plate group
Description: occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions
Study: NCT01540578

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04502043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: * Education~* Hip-specific strengthening exercises~* Functional lower limb strengthening exercises~* Core stability exercises~* Postural balance exercises
Study: NCT02475018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk fortified with plant sterol esters
Description: 250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain milk
Description: 250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
Study: NCT02654899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06815345
Description: PF-06815345 will be administered as a liquid dosage formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06815345
Description: PF-06815345 will be administered as a liquid dosage formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06815345
Description: PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
Study: NCT02197143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrotalcid
Description: 150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrotalcid
Description: 150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
Study: NCT03822195

Intervention type: PROCEDURE
Intervention: Carotid endoarterectomy
Description: Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)

Intervention type: PROCEDURE
Intervention: Carotid endoarterectomy
Description: Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
Study: NCT00733226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OM-85 BV (Broncho-Vaxom)
Description: 3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OM-85 BV (placebo)
Description: 3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
Study: NCT01703845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (high dose) + Olodaterol
Description: Tiotropium + Olodaterol solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (low dose) + Olodaterol
Description: Tiotropium + Olodaterol solution for inhalation
Study: NCT00848393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (High Dose)
Description: Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (Low Dose)
Description: Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (Low Dose) + Dexmedetomidine
Description: Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
Study: NCT00766142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT00575367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AzaSite (azithromycin ophthalmic solution)
Description: One drop ophthalmic solution at Visit 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Description: One drop ophthalmic solution at Visit 2
Study: NCT01935596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaïne
Description: spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lévobupivacaïne
Study: NCT01750086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide 40-mcg subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide 40-mcg subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Injection
Description: One-time Denosumab injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Oral Tablet
Description: weekly alendronate for 8 weeks
Study: NCT02014415

Intervention type: PROCEDURE
Intervention: Liver Biopsy (Biopsy Group Only)
Description: A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
Study: NCT01084239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac Computed Tomography
Description: A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
Study: NCT00799747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: ascending single doses (start dose 2 mg), oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03692689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
Study: NCT03219307

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NOVOCART 3D
Description: Matrix associated autologous chondrocyte implant
Study: NCT00730847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
Study: NCT01124214

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endomicroscopy
Description: endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
Study: NCT02428218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: enteric-coated microtablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric-coated microtablets
Study: NCT00555646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (rose bengal disodium 0.001%)
Description: Treatment plaque area 1: PH-10 with 544 nm LED light illumination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (rose bengal disodium 0.001%)
Description: Treatment plaque area 2: PH-10 with ambient light illumination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: No treatment control.
Study: NCT02396953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide PRF
Study: NCT04517877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Response App
Description: Participants will receive the Caring Light mobile app containing the coping skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Educational/Resources Program
Description: Participants will receive a traditional educational/resources program, containing a workbook and online resources.
Study: NCT00982540

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: caspofungin as preemptive antifungal therapy
Description: 70 mg day 1 followed by 50 mg/day IV
Study: NCT02444351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle
Description: ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: Patients in the control group will not receive any injection on the gastrocnemius muscle.
Study: NCT03412578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage Therapy
Description: Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
Study: NCT01437813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/ Extended release Metformin
Description: One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
Study: NCT00064428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux - UFH not indicated
Description: 2.5mg od, sc (1st dose IV) x 8 days or discharge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - UFH not indicated
Description: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux - UFH indicated
Description: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control - UFH
Description: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
Study: NCT00706914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily aclidinium/formoterol
Description: Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily aclidinium/formoterol
Description: Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily formoterol fumarate
Description: Inhaled formoterol fumarate 12 µg twice-daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to formoterol fumarate
Description: Inhaled placebo to formoterol fumarate once-daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily formoterol fumarate
Description: Inhaled formoterol fumarate 12 μg once-daily in the evening
Study: NCT03535480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF subcutaneously during five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF subcutaneously during five days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASCOT
Description: G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
Study: NCT01805609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study: NCT03845309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Behavior
Description: Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
Study: NCT00772564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral Atorvastatin
Study: NCT00624650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuresis (furosemide) part II
Description: Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuresis (furosemide) part II
Description: Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: 1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis
Description: 1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm.
Study: NCT00006994

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glutamine
Description: 20 cc three times daily for 60 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: l-glutamine placebo
Description: 20 cc three times daily for 60 days
Study: NCT00770133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen/naphazoline
Description: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naphazoline
Description: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
Study: NCT01717547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based treatment
Study: NCT03505255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
Study: NCT00770133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop of vehicle ophthalmic solution at visit 3 and visit 4.
Study: NCT00455520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503
Description: 100, 150, 200, 250 mg twice daily given for up to 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo twice daily for 12 weeks
Study: NCT01733459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: 1 DLBS3233 capsule 100 mg once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: 1 Metformin XR caplet 750 mg twice daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo caplet of Metformin XR
Description: 1 placebo caplet of Metformin XR twice daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule of DLBS3233
Description: 1 placebo capsule of DLBS3233 once daily for 6 months
Study: NCT03505255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 0.9 % is given in the control group
Study: NCT01490359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men Making a Difference HIV/STD Risk Reduction Intervention
Description: Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Control
Description: The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
Study: NCT03372577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Sex Therapy
Description: It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Sex Therapy
Description: It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Routine discharge counseling
Study: NCT01179906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects exercise trained for 48 weeks with personal trainers at a college wellness center

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
Study: NCT02210169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of vancomycin
Description: Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.